In last trading session, Coherus Biosciences Inc (NASDAQ:CHRS) saw 2.66 million shares changing hands with its beta currently measuring 0.89. Company’s recent per share price level of $0.98 trading at -$0.07 or -6.67% at ring of the bell on the day assigns it a market valuation of $113.57M. That closing price of CHRS’s stock is at a discount of -169.39% from its 52-week high price of $2.64 and is indicating a premium of 32.65% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.0 million shares which gives us an average trading volume of 2.09 million if we extend that period to 3-months.
For Coherus Biosciences Inc (CHRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Upright in the red during last session for losing -6.67%, in the last five days CHRS remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.98 price level, adding 16.95% to its value on the day. Coherus Biosciences Inc’s shares saw a change of -28.99% in year-to-date performance and have moved -4.85% in past 5-day. Coherus Biosciences Inc (NASDAQ:CHRS) showed a performance of -16.24% in past 30-days. Number of shares sold short was 30.77 million shares which calculate 18.43 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 83.67% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -512.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -512.24% for stock’s current value.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 53.68M for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -27.36% during past 5 years.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Insiders are in possession of 1.36% of company’s total shares while institution are holding 58.21 percent of that, with stock having share float percentage of 59.02%. Investors also watch the number of corporate investors in a company very closely, which is 58.21% institutions for Coherus Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CHRS for having 11.75 million shares of worth $20.33 million. And as of 2024-06-30, it was holding 10.4236 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4035 of outstanding shares, having a total worth of $18.34 million.
